SRS and Other Local Ablative Strategies in Patients With NSCLC and Oligometastases
Kristin Higgins, MD, Winship Cancer Institute, Atlanta, Georgia, provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated NSCLC patients with oligometastases.
Transcript:
Hello. I'm Dr. Kristin Higgins, a Thoracic Radiation Oncologist at Winship Cancer Institute of Emory University. At the latest, Great Debates and Updates in Lung Cancer. In Brooklyn, New York, we had an exciting agenda. I discussed the oligometastatic paradigm in radiation oncology as well as how radiation technology intersects with that paradigm and really enables radiation oncologists to deliver better, safer, and more effective therapies. As a radiation oncologist, I use a multitude of technologies. These technologies have evolved over time to make treatments safer for our patients. That includes stereotactic radiosurgery and next generation linear accelerator technologies.
We have multiple technologies that now include incorporation of PET CT, for example, into the standard linear accelerator design that could enable us to treat multiple metastatic lesions in one radiation session. We also have immunotherapy and other targeted agents that, with radiation, can make treatments more effective and can allow patients to remain on their systemic therapy while we treat any progressive lesions with targeted radiation therapy. I think, in the end, this leads to more options for our patients, better clinical outcomes and, ultimately, better quality of life. Thank you.
Source:
Higgins, K. SRS and other local ablative strategies. Presented by: Great Debates & Updates in Lung Cancer; October 14-15, 2022; Brooklyn, New York.
